Cardiovascular diseases are the leading cause of morbidity and mortality in the U.S. It has long been documented that the incidence and severity of myocardial infarction has a diurnal variation, with the peak in the early morning. The molecular basis, however, is poorly understood. Also, state-of-the-art flow restoring therapies cannot avoid the ischemic reperfusion (I/R) injury either at the time of heart attack or during revascularization. Kruppel-like zinc finger transcription factors play important roles in multiple aspects of cardiovascular biology. We have characterized the role of Kruppel-like factor 15 (KLF15) in regulating cellular metabolism in the liver and the skeletal muscle. Nascent observations by the applicant suggest a critical role of KLF15 in coordinating catabolism and reactive oxygen species (ROS) clearance in the heart. KLF15 deficient myocardium/cardiomyocytes exhibits increased accumulation of ROS and exaggerated susceptibility to I/R injury. Using next generation sequencing, we discovered that KLF15 governs 75% of the oscillating transcripts in the heart and organize them into two temporal functional clusters, one enriched for catabolic genes coincides with the active phase, another enriched for remodeling and repair genes coincides with the resting phase. Loss of function of KLF15 in the murine heart leads to aberrant oscillation. Finally, KLF15 is significantly reduced in human heart samples with ischemic cardiomyopathy. Using a combination of murine models and molecular/cellular approaches, Dr. Zhang will study the molecular mechanisms of cardiac KLF15 in the dynamic process circadian regulation of fuel utilization and redox homeostasis. In addition, Dr. Zhang will use novel induced pluripotent stem cell derived cardiomyocyte (iPS-CM) technology to extend the studies to human cells. With the support provided by the K08 award, Dr. Zhang's project will lead to a better understanding of the role of KLF15 on the circadian variability of the susceptibility to I/R injury, reveal the molecular mechanism of such regulation and may provide a foundation for the development of novel therapies to limit myocardial injury.
The specific aims of the proposal include: 1. To determine the effect of KLF15 deficiency on cardiac I/R injury: We will use cardiac-specific KLF15 KO mice to assess the cardiac I/R injury, lipid metabolism, ROS and transcriptome in a circadian fashion. 2. To identify and validate key targets of KLF15 in the cardiac circadian gene regulation: We will ChIP-seq to identify direct KLF15 targets and validate them in murine models both in vitro and in vivo. 3. To evaluate the function of KLF15 and its key targets in hiPS-CM: We will assess key findings in murine models in human iPS-CM. The applicant, Dr. Lilei Zhang, a physician-scientist with special interest in cardiogenetics, outlines a 5-year mentored career plan that will build upon her experience in human genetics, molecular biology and clinical medical genetics. Under the guidance of Dr. Mukesh Jain, a recognized leader in transcriptional and cardiovascular biology, Dr. Zhang will use tissue specific murine model combined with genomic tools to study the role of KLF15 in circadian regulation of cardiac metabolism and reduction-oxidation (redox) homeostasis. With assistance from Dr. Anthony Wynshaw-Boris, she will also use (iPS-CM) technology to extend the project to the relevant cell types in human. Dr. Zhang will be mentored by an Advisory Committee composed of highly successful, NIH-funded physician scientists at Case Western Reserve University (CWRU) with expertise in her area of research. This plan is ideally carried out in the Cardiovascular Research Institute (CVRI) at Case Western Reserve University with its distinguished record for training physician-scientists in a rich and collaborative environment. The mentored K08 award will directly advance her scientific development by protecting her effort toward her research project and help her transition into an independent investigator with her own laboratory and R01 funding.
Cardiovascular diseases are the leading cause of morbidity and mortality in the U.S. It has long been documented that the incidence and severity of myocardial infarction has a diurnal variation, with the peak in the early morning. The molecular basis, however, is poorly understood. Also, state-of-the-art flow restoring therapies cannot avoid the ischemic reperfusion (I/R) injury either at the time of heart attack or during revascularizatio. Our preliminary data strongly supports a critical role for transcription factor Kruppel-like factor15 (KLF15) in the circadian variability of myocardium susceptibility to I/R injury. This grant aims to gain a more precise understanding of the role of KLF15 in coordinating catabolism and clearance of the reactive oxygen species in the heart in a circadian fashion and establish a human induced pluripotent stem cell derived cardiomyocyte model to study circadian regulation in the human cardiomyocytes. Heart attacks have the highest incidence and severity in the early morning hours, yet the basis for this is unknown. The current therapy to restore flow does not prevent the cardiac injury, which occurs both during the heart attack itself and the subsequent restoration of blood flow. We have discovered a central 'master' factor that directly regulates 3/4 of the oscillating genes in the heart and coordinates two critical functions of the heart in a circadian fashion (energy production and injury repair). We aim to test if this factor is the key determinant for the diurnal variation in heart attack. We have shown that genetically engineered mice missing this factor experience larger infarcts when given an experimental 'heart attack'. We aim to further study (1) if this alters the result of heart attacks in a circadian fashion; (2) hat are the important downstream targets of this central factor (we have identified at least one); (3) the function of those targets in cells and in whole animals and if restoring either the central factor itself or its key targets can ameliorate the result of heart attacks. In particular, we will establish and verify human cellular models, which build the foundation for future testing of therapy. This factor we propose to study is typically reduced in humans with chronic heart disease. With detailed information of its role in heart attack and through what other factors it exerts protective roles, we will be able to develop novel tests to identify high-risk individuals (based on reduced expression level of this target) and novel therapies (to restore expression of this main factor itself or its key downstream targets). We also aim to develop the platform to be able to test therapeutic agents in human cardiomyocytes during this study.
|Hsieh, Paishiun Nelson; Zhang, Lilei; Jain, Mukesh Kumar (2018) Coordination of cardiac rhythmic output and circadian metabolic regulation in the heart. Cell Mol Life Sci 75:403-416|
|Zhang, Lilei; Zhang, Rongli; Tien, Chih-Liang et al. (2017) REV-ERB? ameliorates heart failure through transcription repression. JCI Insight 2:|
|Shen, Yuyan; Hong, Hong; Sangwung, Panjamaporn et al. (2017) Kruppel-like factor 4 regulates neutrophil activation. Blood Adv 1:662-668|
|Zhang, Rongli; Shen, Yuyan; Zhou, Lin et al. (2017) Short-term administration of Nicotinamide Mononucleotide preserves cardiac mitochondrial homeostasis and prevents heart failure. J Mol Cell Cardiol 112:64-73|
|Zhang, Lilei; Jain, Mukesh K (2016) Beating against the clock. Proc Natl Acad Sci U S A 113:2558-9|